Select Language

Galectin-3

Galectin-3 Overview

English Name	Galectin-3	Approved Drugs	1
Drugs in Clinical Trials	7	Target Synonym	Galactoside-binding protein，GALBP，Epididymis Secretory Sperm Binding Protein，MAC2，Laminin-binding protein，CBP 35，Gal-3，IgE-binding protein，Carbohydrate-binding protein 35，L-31，Lectin L-29，LGALS3，Advanced Glycation End-Product Receptor 3，Lectin， Galactoside-Binding， Soluble， 3，Galactose-Specific Lectin 3，35 KDa Lectin，Mac-2 Antigen，Galectin-3，LGALS2，CBP35，GALIG，GAL3，L31，Galectin 3，MAC-2
Highest Development Stage	Approved

English Name	Galectin-3
Target Synonym	Galactoside-binding protein，GALBP，Epididymis Secretory Sperm Binding Protein，MAC2，Laminin-binding protein，CBP 35，Gal-3，IgE-binding protein，Carbohydrate-binding protein 35，L-31，Lectin L-29，LGALS3，Advanced Glycation End-Product Receptor 3，Lectin， Galactoside-Binding， Soluble， 3，Galactose-Specific Lectin 3，35 KDa Lectin，Mac-2 Antigen，Galectin-3，LGALS2，CBP35，GALIG，GAL3，L31，Galectin 3，MAC-2
Approved Drugs	1
Drugs in Clinical Trials	7
Highest Development Stage	Approved

Galectin-3 Product List

Product Category
Protein (3)
Product Status
Launched (3)
Species
Human (3)
Tag
His Tag (2)His Tag & Avi Tag (1)
Conjugate
Unconjugated (2)Biotin-labeled (1)

Cat. No.	Species	Host	Product Description
GA3-H5129	Human	E. coli	Human Galectin-3 Protein, His Tag
GA3-H5247	Human	HEK293	Human Galectin-3 Protein, His Tag
GA3-H82E3	Human	HEK293	Biotinylated Human Galectin-3 Protein, His,Avitag™

Total: 3

Galectin-3 Background

Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3 / Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3 / Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis.

Galectin-3 Synonyms

Galectin-3,LGALS3,MAC2,Gal-3,35 kDa lectin,CBP 35,GALBP,IgE-binding protein,L-31,Laminin-binding protein,Lectin L-29,Mac-2 antigen

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Olitigaltin	GB-0139; TD-139	Phase 2 Clinical	Lund University Foundation, The University Of Edinburgh	Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis	Details
Galactomannan C	GM-CT-01	Phase 2 Clinical	Galectin Therapeutics Inc	Bile Duct Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Gallbladder Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Prostatic Neoplasms	Details
Selvigaltin	GB-1211; GB1211	Phase 2 Clinical	Galecto Inc	Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck	Details
ProLectin-M		Phase 2 Clinical	BioXyTran Inc	Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Influenza, Human	Details
Gal-400	Gal-400	Phase 1 Clinical	Galecto Inc	Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
Belapectin	GR-MD-02	Phase 1 Clinical	Galectin Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Esophageal and Gastric Varices; Hepatic Insufficiency; Hypertension, Portal; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Psoriasis; Squamous Cell Carcinoma of Head and Neck	Details
SIF-001	SIF001	Phase 1 Clinical	Suninflam Inc	Epilepsy; Neuroinflammatory Diseases	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Ocriplasmin	A-01016; THR-409	Approved	Thrombogenics	Jetrea, Jejetrea	United States	Vitreomacular Adhesion	Thrombogenics Inc	2012-10-17	Arterial Occlusive Diseases; Diabetic macular oedema; Diabetic Retinopathy; Disease Progression; Eye Diseases; Macular Degeneration; Retinal Diseases; Retinal Vein Occlusion; Stroke; Uveitis; Venous Thrombosis; Vitreomacular Adhesion; Vitreous Detachment	Details